Patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less receiving SGLT2 inhibitor therapy also had a significantly lower incidence of death from cardiovascular causes and hospitalization for heart failure than patients without SGLT2 inhibitor therapy in the DAPA-HF trial [5]. The gene discussed is SLC5A2; the disease is heart failure.